From: Anti-Ebola therapy for patients with Ebola virus disease: a systematic review
Agent Citation | Setting (n centres) | Intervention group (n included in analysis) | Control group (n included in analysis) |
---|---|---|---|
Randomized clinical trial | |||
   ZMapp    PREVAIL II Writing    group, 2016 [24] | Liberia, Sierra Leone, Guinea, USA (11 centres) | ZMapp 50 mg/kg IV every 3 days (n = 36) | Standard carea (n = 35) |
Non-randomized single-arm intervention study with concurrent controls | |||
   TKM-130803    Dunning et al., 2016 [25] | Port Loko, Sierra Leone (1 centre) | TKM-130803 infusion 0.3 mg/kg IV daily for up to 7 days (n = 12) | Standard carea (n = 3) |
   Convalescent whole blood    Sahr et al., 2017 [26] | Wilberforce and Hastings, Freetown, Sierra Leone (2 centres) | Convalescent whole blood 450 ml (n = 43) | Standard carea (n = 25) |
   Interferon β-1a    Konde et al., 2017 [27]b | Coyah, Guinea (1 centre for intervention and the majority of control patients) | Interferon-β-1a 30 μg subcutaneously (n = 9) | Standard carea (n = 38) |
Non-randomized single-arm intervention study with historical controls | |||
   Convalescent plasma    van Griensven    et al., 2016 [28] | Conakry, Guinea (1 centre) | Convalescent plasma 200–250 ml (or 10 ml/kg if < 45 kg); two consecutive transfusions with each unit obtained from a separate convalescent donor (n = 84) | Standard carea (n = 418) |
   Favipiravir    Sissoko et al., 2016 [29] | Guinea (Conakry, Gueokedou, Macenta, Nzerekore) (4 centres for intervention patients; control patients from Guinea) | Favipiravir (oral) 6000 mg on day 0, then 2400 mg daily on days 1 to 9 (n = 111) | Standard carea (n = 540) c |
   Favipiravir    Bai et al., 2016 [30] | Jui Town, Sierra Leone (1 centre) | Favipiravir T-705 (oral) 800 mg twice on day 0 and two doses of 600 mg on subsequent days, ranging from 3 to 11 days, until discharge, transfer, or death (n = 39) | Standard care (IV fluids limited)a (n = 85) |
Non-randomized single-arm intervention study without controls | |||
   Brincidofovir    Dunning et al., 2016 [31] | Monrovia, Liberia (1 centre) | Brincidofovir (oral) on day 0, 3, 7, 10, and 14 + standard carea (n = 4) | None |
Retrospective cohort study | |||
   Artesunate-amodiaquine    Gignoux et al., 2016 [32] | Foya, Lofa County, Liberia (1 centre) | Artesunate-amodiaquine (n = 71) | Artemether-lumefantrine (n = 194); no anti-malarial drugs (n = 63) |